BioAge, Novartis team up to discover age-related disease targets

BioAge Labs (NASDAQ:BIOA) and Novartis (NYSE:NVS) are collaborating to discover novel targets for the development of therapies to treat age-related diseases and conditions.

Under the agreement, BioAge (NASDAQ:BIOA) will receive up to $20M in upfront payments and research funding, plus up to $530M in potential milestone payments.

Both companies will have the right to advance targets discovered under the collaboration, with each eligible to receive reciprocal milestone payments and tiered royalties, according to a statement.

BioAge’s (BIOA) stock crashed earlier this month after the company said it was discontinuing a Phase 2 study for its weight-loss drug azelaprag over safety concerns. The drug is licensed from Amgen (AMGN).

The company had been testing azelaprag as both a monotherapy and in combination with Eli Lilly’s (LLY) tirzepatide, also known as Mounjaro and Zepbound.

BioAge (BIOA) held an upsized initial public offering in September.